TF and hepatocellular carcinoma: Using another concept, the glycoprotein transferrin was applied as targeting-ligand and redox-responsive gatekeeper by Chen et al. who could show the same toxicity of the free drug doxorubicin and doxorubicin in transferrin-targeted-MSN in hepatocellular carcinoma cells [49].